Drugs / Madopar
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06729658 | Oct 2017 → Feb 2023 | — | Max Planck Institute for Human Cognitive and Brain Sciences | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04968613 | Jan 2018 → Dec 2021 | Parkinson disease, cognitive disorder | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06034158 | Sep 2023 → Mar 2024 | — | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Madopar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06729658 ↗ |